XORTX Therapeutics Inc.’s Post

Sjögren’s disease is the second most common #autoimmune rheumatic #disease after rheumatoid arthritis. Autoimmune means that the immune system attacks healthy cells in the body. There is currently no cure or specific treatments available for Sjögren’s disease; available #treatments and #therapies are tailored to each patient to try to help reduce the symptoms they are experiencing, avoid complications, and improve their quality of life. This approach, which often involves using several different medications, can take a great deal of effort for some patients, and some medications can cause unavoidable side effects. The KPL-404-C221 Study is testing a #study drug called abiprubart in adults with Sjögren’s disease. Please talk to a study team member to learn more about the KPL-404-C221 Study at 361-905-5025. #joinourstudy #sclamanagement #researchmatters #clinicalresearch #corpuschristi #texas #struggle #Sjögren Kiniksa Pharmaceuticals

February 29 is a rare day; fittingly, it's also Rare Diseases Day.    And while the term 'Rare Disease Day' may evoke a sense of rarity, the reality is - over 300 million people worldwide live with one.    So today, we’re showing our support by featuring our portfolio companies working to improve the well-being and life expectancy of those living with ‘Rare Diseases’.   Certa Therapeutics lead candidate, FT011, holds promise as the first anti-fibrotic and disease-modifying treatment for scleroderma patients. Scleroderma, the most fatal of all rheumatologic diseases, affects approximately 125,000 individuals in the United States alone, with an annual incidence rate of 30 cases per million.   #Respirion Pharmaceuticals is pioneering an inhaled antibiotic combination treatment for cystic fibrosis (CF) patients. This innovative approach aims to provide superior anti-infective performance while enhancing lung function for CF patients of all ages and stages. Cystic fibrosis, a progressive genetic disease, impacts close to 40,000 individuals in the United States, spanning all racial and ethnic groups.   #RareDiseaseDay #CertaTherapeutics #Respirion #Scleroderma #CysticFibrosis #RareDiseaseAwareness"

⚠️ Our online Knowledge Hubs contain extensive coverage of different disease states including: ➡️ AKI ➡️ Anemia & Kidney Disease ➡️ Diabetes & Hypertension ➡️ IgAN ➡️ Kidney Transplantation ...and more! Find them at nephtimes.com.

Understanding Chronic Kidney Disease (CKD): Did you know antihypertensive medication like ACE Inhibitors and Angiotensin II receptor blockers are usually contraindicated or prescribed cautiously in CKD patients due to their impact on kidney function? Check out my article for insights on common comorbid conditions and the medications prescribed in CKD. https://lnkd.in/gs2Cy9HH #healthcareinsights #chronickidneydisease #antihypertensives

Integrins used in inflammatory bowel disease Integrins play a significant role in inflammatory bowel disease (IBD) by mediating leukocyte adhesion and migration to the inflamed gastrointestinal mucosa. In particular, α4β7 integrin and α4β1 integrin are involved in the pathogenesis of IBD. Medications such as vedolizumab target α4β7 integrin to inhibit leukocyte trafficking to the gut, providing therapeutic benefit in IBD management. Additionally, natalizumab targets α4β1 integrin and has shown efficacy in treating Crohn's disease. These integrin-targeted therapies represent important advancements in the treatment of IBD. #drrashiddrugupdates

MTM Vision’s Phase 2, “AI Enhanced Diagnostics & Therapeutics Target Identification,” will focus on further improving how we diagnose and assess the severity of diabetic retinal disease and identify new targets for drug development needed to personalize new treatments to preserve and restore vision loss from diabetes.. To learn more, please visit the link below: https://lnkd.in/etpqn7FK #Diabetes #MTMVision #DiabeticRetinopathy #MaryTylerMoore #T1D #Diagnose #HumanEye

Insurance companies and PBMs should start taking more notice of the long-term savings that Ozempic can provide. In reducing morbidities associated with diabetes and obesity, the short-term output may not be worth considering over the long-term possibilities of high-cost conditions.

Check out the most recent article from our partner, Amicus Therapeutics ! Explore Fabry disease's complexities and dive into its depths. Read the article here: https://lnkd.in/g4HRuanr

For patients with type 2 #diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated with lower risks for all-cause mortality and adverse cardiovascular and kidney events compared with glucagon-like peptide 1 receptor agonist treatment (GLP-1 RA). https://brnw.ch/21wLPmR

#Semaglutide's Breakthrough in #KidneyDisease Disease Management for Type 2 #Diabetes Patients Let's look into this recent development in more detail: - 📊 Novo Nordisk's FLOW trial shows a 24% risk reduction in kidney disease-related events with semaglutide 1.0 mg in type 2 diabetes and chronic kidney disease (CKD) patients. - 💡 The trial, stopped early due to significant efficacy, compared semaglutide with placebo, highlighting its potential as a first GLP-1 treatment for this demographic. - 🌍 Conducted globally across 28 countries, the FLOW trial enrolled 3,533 participants, underlining its extensive and diverse dataset. - 🛠️ #Ozempic®, known for its efficacy in glycemic control, is now poised for label expansion to include #CKD treatment following regulatory approval submissions in 2024. - 🎓 Detailed results are awaited at a scientific conference in 2024, promising further insights into semaglutide's benefits beyond glycemic control. Let's keep the discussion going! What are your views on: - 🤔 How do you foresee semaglutide impacting the standard of care for patients with type 2 diabetes and chronic kidney disease? - 💬 What implications does the early stopping of the FLOW trial have for future clinical research in diabetes and CKD? - 🌟 Given the potential label expansion for Ozempic®, what are your thoughts on the broader implications for patient treatment options and healthcare costs? Please share your thoughts and like / share this post to see more like it! Reach out to #LucidQuest at info@lqventures.com to find out more about what we do and how we can support your brand to thrive! #lucidquest #semaglutide #type2diabetes #chronickidneydisease #Ozempic #FLOWtrial #healthcareinnovation #pharmaceuticalindustry #medicalresearch